がん胎児性抗原市場規模、シェア、成長分析：タイプ別、性別、製品別、検査別、エンドユーザー別、地域別 - 産業予測 2025～2032年

がん胎児性抗原市場規模は2023年に26億米ドルと評価され、2024年の27億2,000万米ドルから2032年には39億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは4.8%で成長する見通しです。

世界のがん胎児性抗原（CEA）市場は力強い成長を遂げており、その主な原動力はがん、特にCEA検査の主要用途である大腸がんの罹患率の上昇です。がんの早期発見とモニタリングへの注目が高まっており、CEAのような腫瘍マーカーへの需要が高まっています。世界のがん罹患率の急増、特に大腸がんは、効率的な診断ソリューションの必要性を高めており、CEAは日常的ながんスクリーニングのための信頼できる腫瘍マーカーです。イムノアッセイやバイオマーカー探索などの診断技術の進歩は、CEA検査の精度と効率を高めています。しかし、特に医療予算が限られている地域では、コストの制約が、特に新興諸国では市場拡大の大きな障壁となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

がん胎児性抗原市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 大腸がん
• 膵臓がん
• 卵巣がん
• 乳がん
• 甲状腺がん
• その他

がん胎児性抗原市場規模：性別： & CAGR（2025-2032）

• 市場概要
• 男性
• 女性

がん胎児性抗原市場規模：製品別& CAGR（2025-2032）

• 市場概要
• CD66a
• CD66b
• CD66c
• CD66d
• CD66e
• CD66f

がん胎児性抗原市場規模：検査別& CAGR（2025-2032）

• 市場概要
• 分子検査
• 血清検査

がん胎児性抗原市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院・クリニック
• 調査機関
• 外科センター
• その他

がん胎児性抗原市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• Quest Diagnostics Incorporated（USA）
• Abbott Laboratories（USA）
• Merck KGaA（Germany）
• Laboratory Corporation of America Holdings（USA）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（USA）
• Creative Diagnostics（USA）
• Aviva Systems Biology Corporation（USA）
• Omega Diagnostics Ltd.（UK）
• RayBiotech, Inc.（USA）
• Boster Biological Technology（USA）
• Diazyme Laboratories Inc.（USA）
• GenScript Corporation（USA）
• Lee BioSolutions（USA）
• Danaher Corporation（USA）
• Novartis AG（Switzerland）
• Agilent Technologies, Inc.（USA）

結論と提言

Carcinoembryonic Antigen Market size was valued at USD 2.6 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 3.96 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The global Carcinoembryonic Antigen (CEA) market is experiencing robust growth, primarily driven by the rising incidence of cancers, particularly colorectal cancer, which is a key application of CEA testing. There is an increasing focus on early cancer detection and monitoring, leading to heightened demand for tumor markers like CEA. The worldwide surge in cancer prevalence, especially colorectal cancer, has intensified the need for efficient diagnostic solutions, with CEA being a trusted tumor marker for routine cancer screenings. Advancements in diagnostic technologies such as immunoassays and biomarker discovery are enhancing the accuracy and efficiency of CEA testing. However, cost constraints, especially in regions with limited healthcare budgets, remain a significant barrier to market expansion, particularly in developing countries.

Top-down and bottom-up approaches were used to estimate and validate the size of the Carcinoembryonic Antigen market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Carcinoembryonic Antigen Market Segments Analysis

Global Carcinoembryonic Antigen Market is segmented by Type, Gender, Product, Test, End User and region. Based on Type, the market is segmented into Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Thyroid Cancer and Others. Based on Gender, the market is segmented into Male and Female. Based on Product, the market is segmented into CD66a, CD66b, CD66c, CD66d, CD66e and CD66f. Based on Test, the market is segmented into Molecular Test and Serology Test. Based on End User, the market is segmented into Hospitals & Clinics, Research Institutes, Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Carcinoembryonic Antigen Market

The rising prevalence of various cancers, particularly colorectal cancer, has significantly increased the demand for reliable tumor markers such as Carcinoembryonic Antigen (CEA). The ability of CEA testing to aid in the early detection and monitoring of cancers is a key factor driving its widespread adoption. As healthcare professionals seek effective ways to identify and track cancer progression, the necessity for accurate biomarkers becomes ever more critical, thus further propelling the growth of the CEA market. This trend underscores the importance of early intervention in improving treatment outcomes and patient survival rates.

Restraints in the Carcinoembryonic Antigen Market

A significant constraint in the Carcinoembryonic Antigen (CEA) market is the cost associated with CEA testing. Affordability is a key concern, especially in regions with limited healthcare funding, which restricts wide accessibility and adoption of this testing method. Additionally, the market faces competition from alternative diagnostic tools and technologies, including advanced imaging techniques and liquid biopsies, which could further divert attention and resources away from a heavy reliance on CEA testing. These factors collectively pose challenges that may impede the growth and widespread implementation of CEA testing in clinical settings.

Market Trends of the Carcinoembryonic Antigen Market

The Carcinoembryonic Antigen (CEA) market is experiencing a notable trend driven by the rising integration of advanced technologies in testing methodologies. Innovations such as novel immunoassays and enhanced biomarker discovery are significantly improving the accuracy and effectiveness of CEA diagnostics. This technological evolution not only enhances cancer detection capabilities but also broadens the application of CEA beyond traditional oncology, encompassing areas such as personalized medicine and preventive healthcare. As healthcare systems increasingly adopt these sophisticated diagnostic tools, the demand for CEA-related products is poised for substantial growth, positioning the market for sustained expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Carcinoembryonic Antigen Market Size by Type & CAGR (2025-2032)

• Market Overview
• Colorectal Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Breast Cancer
• Thyroid Cancer
• Others

Global Carcinoembryonic Antigen Market Size by Gender & CAGR (2025-2032)

• Market Overview
• Male
• Female

Global Carcinoembryonic Antigen Market Size by Product & CAGR (2025-2032)

• Market Overview
• CD66a
• CD66b
• CD66c
• CD66d
• CD66e
• CD66f

Global Carcinoembryonic Antigen Market Size by Test & CAGR (2025-2032)

• Market Overview
• Molecular Test
• Serology Test

Global Carcinoembryonic Antigen Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Research Institutes
• Surgical Centers
• Others

Global Carcinoembryonic Antigen Market Size & CAGR (2025-2032)

• North America (Type, Gender, Product, Test, End User)
  • US
  • Canada
• Europe (Type, Gender, Product, Test, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Gender, Product, Test, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Gender, Product, Test, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Gender, Product, Test, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aviva Systems Biology Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omega Diagnostics Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayBiotech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boster Biological Technology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diazyme Laboratories Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lee BioSolutions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations